Dose Escalation and Expansion Study of HM16390 Alone or With Pembrolizumab in Advanced or Metastatic Solid Tumors
Clinical trial NCT06724016 · RECRUITING
Trial details
- NCT number
- NCT06724016
- Sponsor
- Hanmi Pharmaceutical Company Limited
- Status
- RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2024-12-11
- Primary completion
- 2031-07-01
- Enrollment
- 292
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.